SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent benefit across age and frailty, with no excess hypoglycaemia. Diabzen, [S. l.], v. 4, n. 15, p. 28–29, 2026. Disponível em: https://thediabzen.com/index.php/d/article/view/57. Acesso em: 28 jul. 2026.